Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

2 Pages (Click to Jump) V   1 2 >   
 
  
Reply to this topic

BOT, BOTANIX PHARMACEUTICALS LTD
nipper
post Posted: Oct 23 2019, 12:31 PM
  Quote Post


Posts: 6,456
Thanks: 2246


In Reply To: triage's post @ Oct 22 2019, 08:06 PM

Heading south!

(- so glad I passed)



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
triage
post Posted: Oct 22 2019, 08:06 PM
  Quote Post


Posts: 3,786
Thanks: 1527


In Reply To: triage's post @ Oct 22 2019, 10:39 AM

Results are out! the zit potion is moving to phase 3 trial .... Yay! ... but a major part of the trial showed no statistical significance .... Boo! ... the results from the Australian bit of the trial were great! .... Yay .... but in the US part of the trial the placebo performed better than the drug .... Wha???

On hc, there is a small group of previously-unheard-on-the-BOT-threads posters that are posting negatively and repeatedly and most of the rahrah fan club have gone silent for the time being. One hc poster, Rusty, one of the fan club, is attempting to be rational / analytical and has picked up the disparity between the US and Australian results. It looks to me like they stuffed the trial up by using different products in the US than in Australia and the company is looking to move into phase 3 based on the Australian results. I suspect that Rusty is right that the company's announcement yesterday of having signed up one supplier to provide all future CBD requirements may well be an attempt to make sure this stuff-up does not happen again.

But I guess the bottom line is there is uncertainty in this announcement and as the market dislikes uncertainty the BOT share price is going lower.



--------------------
"The market can stay irrational longer than you can stay solvent." John Maynard Keynes

"The crisis takes a much longer time coming than you think, and then it happens much faster than you would have thought." Rudiger Dornbush

Mozart fixes everything and Messi is a dog

Said 'Thanks' for this post: nipper  
 
triage
post Posted: Oct 22 2019, 10:39 AM
  Quote Post


Posts: 3,786
Thanks: 1527


In Reply To: triage's post @ Jul 30 2019, 09:42 PM

So, the time of judgement for Botanix and its many rabid supporters on hc has arrived. The stage 2 trial of its zit cream was completed last month and the stock has gone into a trading halt to allow for the "top line data" - which, as I learned yesterday, is a legal term - to be released. A few on hc are hedging by saying that they are actually waiting for some other trial results due out early next year. But the bottom line it seems to me is that given the hypothesis is that the anti-inflammatory, anti-microbial effects of CBD make it effective for not only acne, but also atopic dermatisis and psiorias (spelling?), then a poor result from the acne trial bodes badly for future trials for those other skin afflictions.

An interesting side-bar to this trading halt is that a couple of days ago a poster on hc claims he is a researcher and lecturer at the same institution as the lead researcher for the Melbourne part of the trial and apparently the poster claimed that the lead researcher told him that the Botanix product was not effective (I did not read the post before it was moderated but from what others said that appears to be the gist of the claim). Now others on hc have pointed out that the trial was a double blind trial so the researcher would not know which of his patients were treated with the Botanix product and which were treated with a placebo. Fair point, I think.


Also my view is what are the chances that a person smart enough to become a well-regarded specialist in dermatology is dumb enough to tell inside information about a commercial-in-confidence trial to someone he occasionally socialises with who is also smart enough to be a university researcher but is dumb enough to ask and receive inside information and then go onto the largest stock forum in the country and blurt out that inside confidential information. Personally I can imagine maybe one of the two people being momentarily imprudent but both of them? Doesn't past the sniff test for me.
But at the very least, this episode may possibly have brought forward when Botanix releases the results - there was a view that they would time releasing the results with the AGM that is on next week. Even any suggestion that there is trading of the stock when there is the taint of insider information floating about should be enough to bring a halt to trading (even more so if the company finds out that one of their lead researchers has spoken out of turn).
The rahrahness of the BOT threads on hc has all the feel of a mania but as Stavely has shown sometimes behind all the pumping and puffery there is substance. We will find out in the next couple of days whether Botanix is another exception to the rule.



--------------------
"The market can stay irrational longer than you can stay solvent." John Maynard Keynes

"The crisis takes a much longer time coming than you think, and then it happens much faster than you would have thought." Rudiger Dornbush

Mozart fixes everything and Messi is a dog
 
triage
post Posted: Jul 30 2019, 09:42 PM
  Quote Post


Posts: 3,786
Thanks: 1527


In Reply To: nipper's post @ Jul 30 2019, 12:48 PM

nip - the word on hc from a couple who say they have been talking to Botanix is that $35m is going to a US specialist in biotech, Cowan, whilst Bell Potter and Agro the puppet (?) gets the opportunity to try and stag $5m, all done and dusted at 21 cents. What is not yet clear to me is whether Cowan has acquired a takeover blocking stake in Botanix itself or whether it is merely acting as a ticket clipper.


The Botanix threads on hc are dominated by a few butch cheerleaders who demand either fluff or pump posts and they have regathered their senses (from the initial shock of Botanix doing exactly what they declared repeatedly they would not do) and are now spinning this as a positive thing. Yeah nah. Botanix still have not handed out the final report on the early stage psoriasis trial and they are about a month away from getting some prelim feedback about the 2nd stage acne trial. The timing of this cap raise and the fact that it was got away at a 20% discount to yesterday's price smacks to me of Botanix hedging their bets. If the trial results are good then no one will be complaining about whether the share price was 21 cents or 26 cents at the beginning of August 2019 and if the results are disappointing then at least the company has enough in the kitty to try their luck with other product candidates: today's cap raise makes sense either way but does not predict one scenario over the other.




--------------------
"The market can stay irrational longer than you can stay solvent." John Maynard Keynes

"The crisis takes a much longer time coming than you think, and then it happens much faster than you would have thought." Rudiger Dornbush

Mozart fixes everything and Messi is a dog

Said 'Thanks' for this post: nipper  
 
nipper
post Posted: Jul 30 2019, 12:48 PM
  Quote Post


Posts: 6,456
Thanks: 2246


QUOTE
Botanix Pharmaceuticals is seeking a $40 million equity injection on Tuesday. The company tapped brokers Bell Potter Securities and Argonaut to arrange the deal, which would see it place 190.5 million new shares to raise $40 million.

The offer was priced at 21¢ a share which was a 19 per cent discount to the last close, according to terms sent to investors on Tuesday morning. The brokers were calling for bids by 4pm on Tuesday. The deal is expected to be announced on Thursday.

Botanix had a $201 million market capitalisation prior to the raising. Botanix is a clinical stage cannabinoid company based in Perth.

- get a good price run, and the CR follows close behind, for minnows!



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jul 17 2019, 12:09 PM
  Quote Post


Posts: 6,456
Thanks: 2246


In Reply To: nipper's post @ Jun 20 2019, 08:23 PM

QUOTE
• New data has shown that a new drug candidate from Botanix’s cannabidiol antimicrobial platform has potent activity against hypervirulent strains of the bacteria Clostridium difficile

Clostridium difficile is the most commonly acquired hospital infection worldwide and is responsible for over 30,000 deaths each year in the US alone

• Data for AB 2367, Botanix’s new development program, shows that cannabidiol is effective against the super hypervirulent 027 strain, which has been responsible for numerous recent severe outbreaks and deaths

• Studies were conducted in collaboration with world-leading Clostridium difficile researcher Prof. Dena Lyras at Monash Biomedicine Discovery Institute, Department of Microbiology

• This new data adds to the recently announced BTX 1801 study results that MRSA does not develop resistance to cannabidiol, and underpins Botanix’s growing antimicrobial platform
- BOT coming along quite nicely, on vol and market pricing




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 

sentifi.com

Share Cafe Sentifi Top themes and market attention on:


nipper
post Posted: Jun 20 2019, 08:23 PM
  Quote Post


Posts: 6,456
Thanks: 2246


In Reply To: triage's post @ Jun 20 2019, 07:02 PM

interesting how with this Company, and unlike many pharma's that seem to narrow the opportunity set, how there has been a progression with Cannabidiol product applications .... from Acne, to epilepsy, now through to Superbugs. Is this astute research or spreading themselves too thinly?



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
triage
post Posted: Jun 20 2019, 07:02 PM
  Quote Post


Posts: 3,786
Thanks: 1527


In Reply To: nipper's post @ Jun 20 2019, 03:03 PM

A very impressive ASX announcement I have to say. Keen to see what the yanks and Europeans make of it overnight. I am always cautious of the spin that the corporate spruikers put on such developments so am interested in what the UQ researcher reports to a microbiology conference next Monday in the US.



--------------------
"The market can stay irrational longer than you can stay solvent." John Maynard Keynes

"The crisis takes a much longer time coming than you think, and then it happens much faster than you would have thought." Rudiger Dornbush

Mozart fixes everything and Messi is a dog

Said 'Thanks' for this post: nipper  
 
nipper
post Posted: Jun 20 2019, 03:03 PM
  Quote Post


Posts: 6,456
Thanks: 2246


QUOTE
Botanix Pharmaceuticals is enjoying a more than 20 per cent bump on the Australian market following news its product can kill superbugs.

This is the second day in a row that the company has enjoyed a share price lift following data on its cannabidiol (CBD) product, BTX 1801. It told the market yesterday that the product showed positive results when tested in a trial for skin disease.

Botanix told its investors today that BTX 1801 had also been shown to rapidly kill superbugs. Shares in the BOT shot up 25 per cent, before coming back slightly to 21.4 per cent higher at 17c.

The company said that data from a trial showed that despite extensive exposure to CBD, superbugs did not develop resistance to BTX 1801.

BTX 1801 is described by Botanix as a novel topical formulation of cannabidiol, which utilises Botanix’s proprietary skin delivery technology, PermetrexTM, to target bacterial infections in the skin.

Mark Blaskovich from the University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions, who oversaw the study, said the pipeline of new antibiotics in clinical development was way too small to combat the growing threat of antimicrobial resistance.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne

Said 'Thanks' for this post: triage  
 
triage
post Posted: Jun 2 2019, 10:21 AM
  Quote Post


Posts: 3,786
Thanks: 1527


This is probably good news for Botanix (BOT not BOX) which is working through the formal processes of getting several of its trial products approved by the US FDA.


https://www.bloomberg.com/news/articles/201...cannabis-weekly

Botanix uses synthetically produced CBD which means it is using a pure substance, unlike CBD produced from plants which contains varying amounts of CBD and impurities. And it already has two products in phase 2 trials, for severe acne and atopic dermatitis, and one for psoriasis in an early stage safety trial, which if they survive the trials will allow Botanix to seek FDA approval. Pressure for the FDA to go easy on CBD products will be alleviated if it can show that it is working with companies to produce CBD based products that have been proven to meet its standards.

What also separates Botanix products from over-the-counter type products is that the delivery system Botanix uses is able to deliver much higher amounts of CBD under the skin than other products that have been tested.

Anyway, Botanix is late delivering the results from a couple of trials which is rarely a good sign. So it may go the way that most of these pharma start ups go...



--------------------
"The market can stay irrational longer than you can stay solvent." John Maynard Keynes

"The crisis takes a much longer time coming than you think, and then it happens much faster than you would have thought." Rudiger Dornbush

Mozart fixes everything and Messi is a dog

Said 'Thanks' for this post: nipper  
 
 


2 Pages (Click to Jump) V   1 2 >

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING